FCGR2A and malaria: A very recent and complementary publication by Kisalu et al. did not observe significant differences for protection by the CIS43-LS anti-CSP mAb on malaria parasite burden in a mouse model, regardless of whether the Fc was intact or carried the LALA mutation that abrogates FcgR binding (42).